In addition, CSF-CXCL13 serves as a treatment response marker in neuroborreliosis that decreases most strongly and rapidly during therapy, independent of the decrease in the CSF/serum albumin ratio or total cell count [9,39]. The gene discussed is ALB; the disease is Lyme disease.